<DOC>
	<DOC>NCT02098473</DOC>
	<brief_summary>The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.</brief_summary>
	<brief_title>Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Histologic evidence of EoE Clinical symptoms of EoE including dysphagia Primary causes of esophageal eosinophilia other than EoE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>